SONY

Product Data Sheet

Spark YG™ 581 anti-human CD16

Catalog # / Size:	2110350 / 100 tests 2110345 / 25 tests
Clone:	3G8
Isotype:	Mouse IgG1, κ
Immunogen:	Human PMN cells
Reactivity:	Human, Non-human primate
Preparation:	The antibody was purified by affinity chromatography and conjugated with Spark YG™ 581 under optimal conditions.
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA)
Workshop Number:	V NK80
Concentration:	Lot-specific



Human peripheral blood lymphocytes were stained with anti-human CD56 Brilliant Violet 421™ and anti-human CD16 (clone 3G8) Spark YG™ 581 (left), or only stained with anti-human CD56 Brilliant Violet 421™ (right).

Applications:

Applications:	Flow Cytometry
Recommended Usage:	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells in 100 µL staining volume or 5 µL per 100 µL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application. * Spark YG™ 581 has a maximum excitation of 562 nm and a maximum emission of 581 nm.



Application Notes:

The 3G8 antibody clone blocks neutrophil phagocytosis and stimulates NK cell proliferation. It has been reported that this clone interacts with the FcγRIIa and FcγRIIIb receptors causing neutrophil activation and aggregation[18]. Due to this phenomenon staining in whole blood may cause a reduction in the number of granulocytes or alter their scatter profile.

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections[6], immunoprecipitation[3], stimulation of NK cell proliferation[4], blocking of phagocytosis[5], and blocking of immunoglobulin binding to FcγRIII[7,8]. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 302049, 302050, 302057, 302058).

Application References:

1. Knapp W, *et al.* Eds. 1989. Leucocyte Typing IV. Oxford University Press. New York.
2. Schlossman S, *et al.* Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
3. Edberg J, *et al.* 1997. *J. Immunol.* 159:3849. (IP)
4. Hoshino S, *et al.* 1991. *Blood* 78:3232. (Stim)
5. Tamm A, *et al.* 1996. *Immunol.* 157:1576. (Block)
6. Da Silva DM, *et al.* 2001. *Int. Immunol.* 13:633. (IHC)
7. Holl V, *et al.* 2004. *J. Immunol.* 173:6274. (Block)
8. Hober D, *et al.* 2002. *J. Gen. Virol.* 83:2169. (Block)
9. Brainard DM, *et al.* 2009. *J. Virol.* 83:7305. PubMed
10. Smed-Sörensen A, *et al.* 2008. *Blood* 111:5037. (Block) PubMed
11. Timmerman KL, *et al.* 2008. *J. Leukoc. Biol.* 84:1271. (FC) PubMed
12. Yoshino N, *et al.* 2000. *Exp. Anim. (Tokyo)* 49:97. (FC)
13. Rout N, *et al.* 2010. *PLoS One* 5:e9787. (FC)
14. Kim WK, *et al.* 2006. *Am. J. Pathol.* 168:822. (FC)
15. Boltz A, *et al.* 2011. *J. Biol Chem.* 286:21896. PubMed
16. Wu Z, *et al.* 2013. *J. Virol.* 87:7717. PubMed
17. Peterson VM, *et al.* 2017. *Nat. Biotechnol.* 35:936. (PG)
18. Vossebeld PJ, et al. 1997. *Biochem J.* 323:87-94 (Stim)

Description:

CD16 is known as low affinity IgG receptor III (FcγRIII). It is expressed as two distinct forms (CD16a and CD16b). CD16a (FcγRIIIA) is a 50-65 kD polypeptide-anchored transmembrane protein. It is expressed on the surface of NK cells, activated monocytes, macrophages, and placental trophoblasts in humans. CD16b (FcγRIIIB) is a 48 kD glycosylphosphatidylinositol (GPI)-anchored protein. Its extracellular domain is over 95% homologous to that of CD16a, and it is expressed specifically on neutrophils. CD16 binds aggregated IgG or IgG-antigen complex which functions in NK cell activation, phagocytosis, and antibody-dependent cell-mediated cytotoxicity (ADCC).

Antigen References:

1. Fleit H, *et al.* 1982. *P. Natl. Acad. Sci. USA* 79:3275.
2. Stroncek D, *et al.* 1991. *Blood* 77:1572.
3. Wirthmueller U, *et al.* 1992. *J. Exp. Med.* 175:1381.